Synaptogenix (SNPX) Competitors $2.96 -0.02 (-0.67%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends SNPX vs. GOVX, TLPH, AIM, CLDI, TENX, NRXP, MTEX, KZIA, AWH, and SLGLShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include GeoVax Labs (GOVX), Talphera (TLPH), AIM ImmunoTech (AIM), Calidi Biotherapeutics (CLDI), Tenax Therapeutics (TENX), NRx Pharmaceuticals (NRXP), Mannatech (MTEX), Kazia Therapeutics (KZIA), Aspira Women's Health (AWH), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. GeoVax Labs Talphera AIM ImmunoTech Calidi Biotherapeutics Tenax Therapeutics NRx Pharmaceuticals Mannatech Kazia Therapeutics Aspira Women's Health Sol-Gel Technologies GeoVax Labs (NASDAQ:GOVX) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Do institutionals & insiders believe in GOVX or SNPX? 6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by company insiders. Comparatively, 4.3% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to GOVX or SNPX? In the previous week, GeoVax Labs' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score. Company Overall Sentiment GeoVax Labs Neutral Synaptogenix Neutral Which has better earnings and valuation, GOVX or SNPX? Synaptogenix has lower revenue, but higher earnings than GeoVax Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$300.68K53.56-$25.97MN/AN/ASynaptogenixN/AN/A-$6.04MN/AN/A Which has more volatility & risk, GOVX or SNPX? GeoVax Labs has a beta of 3.1, indicating that its stock price is 210% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Is GOVX or SNPX more profitable? Synaptogenix's return on equity of -7.45% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax LabsN/A -852.60% -326.87% Synaptogenix N/A -7.45%-5.65% Does the MarketBeat Community favor GOVX or SNPX? GeoVax Labs received 16 more outperform votes than Synaptogenix when rated by MarketBeat users. Likewise, 94.74% of users gave GeoVax Labs an outperform vote while only 66.67% of users gave Synaptogenix an outperform vote. CompanyUnderperformOutperformGeoVax LabsOutperform Votes1894.74% Underperform Votes15.26%SynaptogenixOutperform Votes266.67% Underperform Votes133.33% Do analysts rate GOVX or SNPX? GeoVax Labs currently has a consensus price target of $12.67, suggesting a potential upside of 559.72%. Synaptogenix has a consensus price target of $14.00, suggesting a potential upside of 372.97%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts clearly believe GeoVax Labs is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryGeoVax Labs beats Synaptogenix on 9 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.03M$7.02B$5.40B$8.53BDividend YieldN/A7.97%5.15%4.14%P/E RatioN/A9.53113.7615.14Price / SalesN/A385.111,483.0493.53Price / CashN/A47.3339.7134.04Price / Book0.125.324.665.01Net Income-$6.04M$153.56M$119.06M$225.46M7 Day Performance-3.93%0.12%0.79%0.37%1 Month Performance-1.33%15.23%5.65%3.57%1 Year Performance-58.95%41.16%36.80%29.42% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix1.7637 of 5 stars$2.96-0.7%$14.00+373.0%-58.7%$4.03MN/A0.004Negative NewsGOVXGeoVax Labs3.2243 of 5 stars$1.92-2.5%$12.67+559.7%-74.9%$16.10M$300,677.000.0017TLPHTalphera2.4262 of 5 stars$0.92-2.1%$4.50+389.1%N/A$15.63M$650,000.00-1.4419AIMAIM ImmunoTech1.3085 of 5 stars$0.26flat$3.00+1,049.0%-43.7%$15.32M$201,000.00-0.4620CLDICalidi Biotherapeutics2.1745 of 5 stars$1.35+14.4%$16.67+1,134.6%N/A$15M$50,000.000.0041Gap UpHigh Trading VolumeTENXTenax Therapeutics3.2034 of 5 stars$4.49+2.3%$170.67+3,705.3%-69.7%$14.97MN/A0.009News CoverageNRXPNRx Pharmaceuticals1.5874 of 5 stars$1.39+0.7%$31.50+2,174.4%-95.5%$14.89MN/A-0.512MTEXMannatech0.8721 of 5 stars$7.82flatN/A-9.5%$14.74M$122.38M-12.41250Upcoming EarningsAnalyst ForecastNews CoverageKZIAKazia Therapeutics1.6853 of 5 stars$5.52+2.2%$20.00+262.3%+35.7%$14.55M$20,000.000.0012AWHAspira Women's Health1.1844 of 5 stars$0.90flat$4.40+388.9%-80.8%$14.45M$9.15M-0.62110Analyst ForecastGap UpSLGLSol-Gel Technologies2.4605 of 5 stars$0.51+4.1%$5.00+880.2%-60.8%$14.21M$1.55M-0.9450Gap Up Related Companies and Tools Related Companies GeoVax Labs Alternatives Talphera Alternatives AIM ImmunoTech Alternatives Calidi Biotherapeutics Alternatives Tenax Therapeutics Alternatives NRx Pharmaceuticals Alternatives Mannatech Alternatives Kazia Therapeutics Alternatives Aspira Women's Health Alternatives Sol-Gel Technologies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNPX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
